Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-01-11FDA Approved: CELECOXIB — Supplemental Application (NIVAGEN PHARMACEUTICALS, INC.)
The FDA approved a supplemental application for Celecoxib submitted by NIVAGEN Pharmaceuticals, Inc., for a generic Celecoxib product.
-
FDA approval · 2022-01-07FDA Approved: MELOXICAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for meloxicam, authorizing the generic NSAID product. This marks regulatory…
-
FDA approval · 2022-01-07FDA Approved: MELOXICAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for MELOXICAM (meloxicam) from Aurobindo Pharma Limited.
-
FDA approval · 2022-01-05FDA Approved: CELECOXIB — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for a generic celecoxib product (Celecoxib) under ANDA 202240.
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Clinical Follow-up of Anti-Carbamylated Antibody Status in Rheumatoid Arthritis
A completed clinical trial follow-up study evaluating anti-carbamylated antibody status in rheumatoid arthritis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate [Phase 2]
Phase 2 trial evaluating brodalumab (AMG 827) in rheumatoid arthritis patients with inadequate response to methotrexate has completed with r…
-
FDA approval · 2021-12-17FDA Approved: YUSIMRY — Original Application (Coherus BioSciences Inc)
FDA approved YUSIMRY (adalimumab-aqvh) from Coherus BioSciences in an original biologics license application, likely as a biosimilar to adal…
-
CLINICAL_TRIALS trial_result · 2021-12-16Clinical Trial Update: PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis [Phase 3]
Phase 3 study assessing pharmacokinetic similarity in rheumatoid arthritis completed with results posted.
-
FDA approval · 2021-12-14FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc. The submission status …
-
FDA approval · 2021-12-14FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc, resulting in updated …
-
CLINICAL_TRIALS trial_result · 2021-12-10Clinical Trial Update: Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study. [Phase 4]
Phase 4 feasibility study comparing JAK-inhibitor versus TNF-inhibitor therapy for rheumatoid arthritis, focusing on early changes in pain, …
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate [Phase 3]
A Phase 3 trial update on discontinuing methotrexate in rheumatoid arthritis patients who achieve remission with upadacitinib plus methotrex…
-
CLINICAL_TRIALS trial_result · 2021-12-06Clinical Trial Update: Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate [Phase 2]
Phase IIb dose-ranging trial of BMS-945429 in methotrexate-not-responsive rheumatoid arthritis completed; results posted in 2021.
-
FDA approval · 2021-12-02FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan (rituximab) filed by Genentech, Inc., resulting in updated labeling for the product.
-
FDA approval · 2021-12-02FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) from Pfizer Laboratories Div Pfizer Inc. The approval authorizes the ex…
-
CLINICAL_TRIALS trial_result · 2021-11-26Clinical Trial Update: Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis [Phase 1, Phase 2]
Clinical trial update for AMG 827 in adults with rheumatoid arthritis across phase 1 and phase 2, with results posted.
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) [Phase 2]
Phase 2 trial assessing safety and effectiveness of the Live Zoster Vaccine in patients using anti-TNF therapy for inflammatory diseases, wi…
-
CLINICAL_TRIALS trial_result · 2021-11-18Clinical Trial Update: Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate [Phase 3]
A Phase 3 trial comparing BAT1806 to RoActemra in rheumatoid arthritis patients with inadequate response to methotrexate has completed.
-
CLINICAL_TRIALS trial_result · 2021-11-18Clinical Trial Update: The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis [Phase 2]
Phase 2 clinical trial update for BCD-089 (aIL6R) in seropositive rheumatoid arthritis has completed.
-
CLINICAL_TRIALS trial_result · 2021-11-17Clinical Trial Update: A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis [Phase 3]
A Phase 3 study comparing CT-P17 to Humira in active rheumatoid arthritis has completed; results were posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-11-17Clinical Trial Update: A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis [Phase 3]
A completed Phase 3 trial evaluating the usability of a subcutaneous auto-injector for CT-P17 in patients with active rheumatoid arthritis.
-
CLINICAL_TRIALS trial_result · 2021-11-10Clinical Trial Update: Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission [Phase 4]
Phase 4 trial update shows non-inferiority of reduced-dose Rituximab in rheumatoid arthritis patients with low disease activity or in remiss…
-
FDA approval · 2021-11-01FDA Approved: AZULFIDINE EN-TABS — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Azulfidine EN-Tabs (sulfasalazine) from Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2021-11-01Clinical Trial Update: Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate [Phase 3]
Phase 3 trial evaluating efficacy and safety of the selective JAK1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequ…
-
FDA approval · 2021-10-25FDA Approved: METHOTREXATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Methotrexate by Hikma Pharmaceuticals USA Inc. (ANDA089342).